Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.

Xiaochuan Liu,Aoli Wang,Xiaofei Liang,Cheng Chen,Juanjuan Liu,Zheng Zhao,Hong Wu,Yuanxin Deng,Li Wang,Beilei Wang,Jiaxin Wu,Feiyang Liu,Stacey M Fernandes,Sophia Adamia,Richard M Stone,Ilene A Galinsky,Jennifer R Brown,James D Griffin,Shanchun Zhang,Teckpeng Loh,Xin Zhang,Wenchao Wang,Ellen L Weisberg,Jing Liu,Qingsong Liu

DOI: https://doi.org/10.18632/oncotarget.8702

2016-01-01

Oncotarget

Abstract:PI3Kδ is predominately expressed in leukocytes and has been found overexpressed in B-cell related malignances such as CLL and AML. We have discovered a highly selective ATP competitive PI3Kd inhibitor PI3KD-IN-015, which exhibits a high selectivity among other PI3K isoforms in both biochemical assays and cellular assay, meanwhile did not inhibit most of other protein kinases in the kinome. PI3KD-IN-015 demonstrates moderately anti-proliferation efficacies against a variety of B-cell related cancer cell lines through down-regulate the PI3K signaling significantly. It induced both apoptosis and autophagy in B-cell malignant cell lines. In addition, combination of autophagy inhibitor Bafilomycin could potentiate the moderate anti-proliferation effect of PI3KD-IN-015. PI3KD-IN-015 shows anti-proliferation efficacy against CLL and AML patient primary cells. Collectively, these results indicate that PI3KD-IN-015 may be useful drug candidate for further development of anti-B-cell related malignances therapies.